Earnings Call Summary | ADC Therapeutics(ADCT.US) Q4 2023 Earnings Conference
Earnings Call Summary | ADC Therapeutics(ADCT.US) Q4 2023 Earnings Conference
The following is a summary of the ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript:
以下是ADC Therapeutics SA（ADCT）2023年第四季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
ADC reported Q4 revenue of $16.6 million, indicating double-digit sequential sales growth.
Despite increase in sales, Q4 net sales dropped by 16% YoY due to higher gross-to-net due to discounted drug rebate and lower volume.
A 24% decrease in operating expenses (non-GAAP), excluding stock-based compensation, is achieved due to driving operating efficiencies and reducing R&D expenditure.
The company reported a net loss of $85 million, or $1.03 per share for Q4 and a total net loss for 2023 at $240 million, or $2.94 per share.
ADC Therapeutics ended 2023 with $278.6 million cash, a decrease of $32 million from the previous quarter.
ADC公佈的第四季度收入爲1,660萬美元，表明連續兩位數的銷售增長。
儘管銷售額有所增加，但第四季度的淨銷售額同比下降了16％，這是由於藥品折扣折扣和銷量減少導致的總淨銷售額增加。
由於提高了運營效率和減少了研發支出，運營支出（非公認會計准則）（不包括股票薪酬）減少了24％。
該公司報告第四季度淨虧損8500萬美元，合每股虧損1.03美元，2023年淨虧損總額爲2.4億美元，合每股虧損2.94美元。
截至2023年，ADC Therapeutics的現金爲2.786億美元，比上一季度減少了3200萬美元。
Business Progress:
業務進展：
ADC continues its advances in clinical value drivers, particularly ZYNLONTA, expected to generate annual peak sales over $0.5 billion and focusing on its developing solid tumor pipeline including ADCT-601 and emerging antibody drug conjugates (ADCs).
Continual progress in clinical trials like LOTIS-5, LOTIS-7 and a Phase 1 study of ADCT-601 have shown promising results.
Increased attention on developing antibody-drug conjugates utilizing an exatecan-based platform.
In 2024, ADC has numerous potential value-driving milestones including disciplined expense management to fund key pipeline programs and maintain their expected cash runway into Q4 of 2025.
ADC expects ZYNLONTA revenues in the US to cover all expenses associated with its commercialization.
The company, focusing on internal growth or through partnerships, plans to pursue multiple ADC candidates in parallel for solid tumors.
ADC繼續在臨床價值驅動因素方面取得進展，尤其是ZYNLONTA，預計年銷售額將超過5億美元，並專注於開發包括 ADCT-601 和新興抗體藥物偶聯物 (ADC) 在內的實體瘤產品線。
LOTIS-5、LOTIS-7 等臨床試驗的持續進展以及 ADCT-601 的1期研究顯示出令人鼓舞的結果。
越來越關注利用基於exatecan的平台開發抗體藥物偶聯物。
2024年，ADC有許多潛在的價值驅動里程碑，包括嚴格的支出管理，爲關鍵管道項目提供資金，並將預期的現金流維持到2025年第四季度。
ADC預計，ZYNLONTA在美國的收入將涵蓋與其商業化相關的所有費用。
該公司專注於內部增長或通過合作伙伴關係，計劃同時開發多種用於實體瘤的ADC候選藥物。
More details: ADC Therapeutics IR
更多詳情： ADC 療法 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。